# US 2010/0247676 A1 · Compositions and methods for treatment of hemorrhage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247676 A1
- Document ID: US20100247676A1
- Status: Published application
- Kind: A1
- Application number: 12/411,548
- Filed: 2009-03-26
- Published: 2010-09-30
- Earliest claimed: 2009-03-26
- Assignees: Warsaw Orthopedic, Inc.
- Inventors: Josee ROY
- Web page: https://patentgrep.com/patent/US20100247676A1

## CPC

- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/08: acyclic, e.g. paraformaldehyde
- A61K 31/74: Synthetic polymeric materials
- A61K 31/77: of oxiranes
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent.

## Claims

### Claim 1

A method of treating a hemorrhage comprising:
diagnosing one or more hemorrhaging vessels in a patient; and
administering to the patient a formulation of a vessel closing compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the formulation comprises between about 0.1% to about 45% weight per volume of the vessel closing compound.

### Claim 3 (depends on 1)

The method of claim 1, wherein the vessel closing compound comprises a hydrophilic polymer.

### Claim 4 (depends on 1)

The method of claim 1, wherein the vessel closing compound comprises polyethylene glycol (PEG).

### Claim 5 (depends on 1)

The method of claim 1, wherein hemorrhaging is induced by a mechanical, an electrical, a biological, or a chemical injury.

### Claim 6 (depends on 1)

The method of claim 1, wherein the formulation further comprises an active agent that can modify blood flow.

### Claim 7 (depends on 6)

The method of claim 6, wherein the active agent can form an ionic bond with the vessel closing agent.

### Claim 8 (depends on 6)

The method of claim 6, wherein the active agent is magnesium.

### Claim 9 (depends on 6)

The method of claim 6, wherein the concentration of the active agent is about 0.1 to about 20% weight per volume.

### Claim 10 (depends on 1)

The method of claim 1, wherein the formulation is administered at a dosing rate of at least about 0.1 to about 10 ml/kg.

### Claim 11 (depends on 1)

The method of claim 1, wherein the formulation is administered intravenously or locally.

### Claim 12 (depends on 1)

The method of claim of claim 1, wherein the formulation is administered locally using a pulsative device.

### Claim 13

A method of treating a hemorrhage comprising:
diagnosing one or more hemorrhaging vessels in a patient; and
administering to the patient a composition comprising PEG and about 0.1% and about 20% weight per volume of an active agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition is administered at a dosing rate of at least about 0.1 to about 10 ml of composition per kg of patient's weight.

### Claim 15 (depends on 13)

The method of claim 13, wherein the active agent is a compound comprising magnesium.

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition comprises between about 20 to about 45% weight per volume of PEG.

### Claim 17

A composition for treatment of a hemorrhage comprising about 20 to about 45% weight per volume of PEG and about 0.1% to about 20% weight per volume of an active agent.

### Claim 18 (depends on 13)

The composition of claim 13, wherein the active agent is a compound comprising magnesium.

### Claim 19

A composition for treatment of a hemorrhage comprising about 0.1% to about 20% weight per volume of an active agent.
